ArticleAlzheimer's research & therapy2011
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.
Article in Alzheimer's research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 56 citations in OpenAlex.
- Feasibility of short imaging protocols for [European journal of nuclear medicine and molecular imaging · 2026Article
- Curing the brain: in search for new astrocyte-specific therapies.Experimental & molecular medicine · 2026Review
- Chemical exchange saturation transfer MRI for neurodegenerative diseases: An update on clinical and preclinical studies.Neural regeneration research · 2026Article
- Early functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer's disease mutations.Translational psychiatry · 2026Article
- Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer's disease with multi-modal PET and plasma GFAP.Molecular neurodegeneration · 2023Article
- Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.Brain : a journal of neurology · 2023Article
- Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment.Metabolic brain disease · 2022Review
- Turn-on chemiluminescence probes and dual-amplification of signal for detection of amyloid beta species in vivo.Nature communications · 2020Article
- Tau PET imaging in neurodegenerative tauopathies-still a challenge.Molecular psychiatry · 2019Review
- Imaging Aβ and tau in early stage Alzheimer's disease with [EJNMMI research · 2018Article
- Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening.Scientific reports · 2017Article
- Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).Molecular imaging and biology · 2017Review
- Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised byScientific reports · 2017Article
- Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-β Deposition in the Brain.Molecular imaging and biology · 2016Article
- Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography.Scientific reports · 2015Article
- Preclinical Comparison of the Amyloid-β Radioligands [(11)C]Pittsburgh compound B and [(18)F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis.Molecular imaging and biology · 2015Article
- Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients.European journal of nuclear medicine and molecular imaging · 2014Article
- Serum metabolomic biomarkers of dementia.Dementia and geriatric cognitive disorders extra · 2014Article
- Neuroimaging of dementia in 2013: what radiologists need to know.European radiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent progress in molecular imaging has provided new important knowledge for further understanding the time course of early pathological disease processes in Alzheimer's disease (AD). Positron emission tomography (PET) amyloid beta (Aβ) tracers such as Pittsburgh Compound B detect increasing deposition of fibrillar Aβ in the brain at the prodromal stages of AD, while the levels of fibrillar Aβ appear more stable at high levels in clinical AD. There is a need for PET ligands to visualize smaller forms of Aβ, oligomeric forms, in the brain and to understand how they interact with synaptic activity and neurodegeneration. The inflammatory markers presently under development might provide further insight into the disease mechanism as well as imaging tracers for tau. Biomarkers measuring functional changes in the brain such as regional cerebral glucose metabolism and neurotransmitter activity seem to strongly correlate with clinical symptoms of cognitive decline. Molecular imaging biomarkers will have a clinical implication in AD not only for early detection of AD but for selecting patients for certain drug therapies and to test disease-modifying drugs. PET fibrillar Aβ imaging together with cerebrospinal fluid biomarkers are promising as biomarkers for early recognition of subjects at risk for AD, for identifying patients for certain therapy and for quantifying anti-amyloid effects. Functional biomarkers such as regional cerebral glucose metabolism together with measurement of the brain volumes provide valuable information about disease progression and outcome of drug treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.